Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

OMS103HP-S

Other · developed by Omeros

Phase 3 Most advanced trial (none active)

OMER Developer

1 Registered trials

What is OMS103HP-S?

OMS103HP-S is a proprietary formulation for injection into surgical irrigation solution during meniscectomy procedures for meniscal tear.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Musculoskeletal
Developer: Omeros Corporation (OMER)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01406561	Phase 3	Meniscal Tear	Completed	OMER

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Meniscal Tear

More from Omeros

Narsoplimab FDA approved OMS103HP Phase 3 OMS201 Phase 1/2 OMS643762 Phase 2 Zaltenibart Phase 2

Sources

ClinicalTrials.gov NCT01406561

Updated Oct 3, 2026. Something wrong or missing? Report it on the OMER page.

Follow OMER, the company behind OMS103HP-S

See OMER's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OMER catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z